Characteristics and treatment regimens across ERS SHARP severe asthma registries.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authorsvan Bragt, Job J M H
Adcock, Ian M
Bel, Elisabeth H D
Ten Brinke, Anneke
Canonica, Giorgio W
Chung, Kian Fan
Richards, Levi B
Sont, Jacob K
Vijverberg, Susanne J H
Weersink, Els J M
Wagers, Scott S
Maitland-van der Zee, Anke H
MetadataShow full item record
Citationvan Bragt JJMH, Adcock IM, Bel EHD, et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J. 2020;55(1):1901163. Published 2020 Jan 9. doi:10.1183/13993003.01163-2019
AbstractLittle is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
RightsCopyright ©ERS 2020.
- Omalizumab for asthma in adults and children.
- Authors: Normansell R, Walker S, Milan SJ, Walters EH, Nair P
- Issue date: 2014 Jan 13
- Anti-IL5 therapies for asthma.
- Authors: Farne HA, Wilson A, Powell C, Bax L, Milan SJ
- Issue date: 2017 Sep 21
- Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
- Authors: Müller V, Gálffy G, Orosz M, Kováts Z, Odler B, Selroos O, Tamási L
- Issue date: 2016
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.
- Authors: Cates CJ, Karner C
- Issue date: 2013 Apr 30
- Inhaled fluticasone at different doses for chronic asthma in adults and children.
- Authors: Adams NP, Bestall JC, Jones PW, Lasserson TJ, Griffiths B, Cates C
- Issue date: 2005 Jul 20